Drugs / Oxycodone
Oxycodone
also known as
oxycodone hydrochloride · Oxycodone HCl · Oxycontin · OxyNorm · Percocet · Oxycodone-Acetaminophen · OXY PR · Oxycodone CR · +77 more
Other / unclassified targets OPRM1 via activation
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | OXYCODONE HYDROCHLORIDE | — | 2021-07-21 | fda.gov ↗ |
| Label expansion | US (FDA) | XTAMPZA ER | — | 2017-11-06 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | OXYCONTIN | — | 2013-04-16 – 2015-08-13 | fda.gov ↗ |
| Approved | US (FDA) | PERCODAN | — | 1950-04-12 | fda.gov ↗ |
Trials 211 · started per year
today
US approved 1950
1
2
2
3
3
2
9
5
4
9
10
10
11
8
9
12
12
6
21
14
9
7
8
11
10
9
4
19481949195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT06435949 | Jul 2024 → Jun 2026 | — | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05846451 | Jun 2023 → Nov 2026 expected | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT03958474 | Aug 2019 → Jul 2025 | opiate dependence | University of Kentucky | Completed | No outcome recorded |
| Phase 0 | NCT03317730 | May 2018 → Dec 2019 | head and neck cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 0 | NCT03393364 | Apr 2018 → Jun 2020 | urinary system disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT06484439 | Feb 2018 → Nov 2021 | impacted teeth, multiple, neuropathy, painful | United States Naval Medical Center, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT04587115 | Jun 2017 → Jun 2019 | drug dependence | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 138 trials | ||||||
| Phase 1 | NCT07223450 | Jun → Oct 2025 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1 | NCT05485012 | Aug 2023 → Mar 2025 | cannabis dependence | Shanna Babalonis, PhD | Completed | No outcome recorded |
| Phase 1 | NCT05730062 | Mar 2023 → Jan 2025 | anxiety disorder, depressive disorder, respiratory underresponsiveness to hypoxia and hypercapnia | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT05742256 | Mar 2023 → Jul 2024 | — | Qianfoshan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05114265 | Feb → Oct 2022 | — | Kures, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03705559 | Jun 2019 → Feb 2024 | cannabis dependence | Shanna Babalonis, PhD | Completed | No outcome recorded |
| Phase 1 | NCT03679949 | Apr 2019 → Dec 2022 | substance abuse | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 1 | NCT04315181 | Mar 2019 → May 2023 | substance-related disorder | Sharon Walsh | Completed | No outcome recorded |
| Phase 1 | NCT03640247 | Nov 2018 → Dec 2019 | parathyroid gland disorder, thyroid gland disorder | MetroHealth Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT03802227 | Oct 2018 → Dec 2019 | — | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT03475862 | May → Jul 2017 | opioid abuse | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02824276 | Jan 2017 → Dec 2022 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02966860 | Aug → Sep 2016 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT02536209 | Aug → Nov 2015 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02531906 | Apr 2015 → Jun 2018 | head and neck squamous cell carcinoma, stomatitis | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02165930 | Jul → Aug 2014 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02880475 | Jun 2014 → Jun 2015 | chronic pain syndrome | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02117583 | Apr → Aug 2014 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02089295 | Apr → Jun 2014 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02059915 | Apr → Jul 2014 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01924676 | Aug → Oct 2013 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01779492 | Apr → Jun 2013 | — | GL Pharm Tech Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01717027 | Nov 2012 → Jan 2013 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01552850 | Apr → Jun 2012 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01552863 | Mar → Sep 2012 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01557257 | Mar → May 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01456507 | Oct 2011 → Jan 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01643772 | May 2011 → Jul 2012 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01160614 | Jul 2010 → Aug 2011 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 1 | NCT01530542 | Jul → Sep 2010 | chronic pain syndrome, opioid abuse | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01127906 | Jun → Sep 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01482936 | May 2010 → Apr 2011 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00864357 | Oct 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00864526 | Oct 2006 | — | Actavis Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00853892 | Apr 2005 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT00853320 | Feb 2003 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT00853736 | Feb 2003 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT00853216 | Jan → Feb 2003 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06757140 | Apr 2025 → Jan 2029 expected | — | Shanna Babalonis, PhD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04791761 | Apr 2021 → Jul 2023 | adenoid hypertrophy, substance-related disorder | David Chi, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT04223609 | Feb 2020 → Apr 2022 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT03618823 | Oct 2018 → May 2020 | adenoid hypertrophy | David Chi, MD | Terminated | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT05265052 | Dec 2026 expected | — | 3D Medicines | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06837857 | Apr 2025 → Jul 2029 expected | chronic pain syndrome | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT04676802 | Dec 2021 → Feb 2027 expected | neuropathy, painful, osteoarthritis, hand | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT04316559 | Dec 2021 → Feb 2025 | opiate dependence | National Institute on Drug Abuse (NIDA) | Terminated | No outcome recorded |
| Phase 2 | NCT03792295 | Jul → Dec 2021 | — | Khashayar Vaziri | Withdrawn | No outcome recorded |
| Phase 2 | NCT05463367 | Jan 2021 → Jun 2025 overdue | chronic pain syndrome, opiate dependence, substance abuse | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03906721 | Feb 2019 → Nov 2021 | spinal cord injury | Spaulding Rehabilitation Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03588910 | Aug 2018 → Jul 2019 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02541396 | Oct → Dec 2015 | — | iX Biopharma Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01915147 | Jul 2013 → Feb 2015 | chronic pain syndrome | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2 | NCT01871285 | Jun 2013 → Jul 2014 | — | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT01030406 | Jan → Feb 2010 | opioid abuse | Acura Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00818493 | Feb → Jul 2009 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00637975 | Sep 2007 → Dec 2010 | cancer | Associazione Progetto Oncologia UMAN.A | Completed | No outcome recorded |
| Phase 2 | NCT00734461 | Aug 2007 → Mar 2009 | opioid abuse | Pain Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00478101 | Feb 2006 → Apr 2007 | — | Gachon University Gil Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00000273 | Aug 1995 → Nov 2005 | heroin dependence | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03805386 | Jan 2019 → Apr 2020 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT02601586 | Sep 2016 → Nov 2020 | Parkinson disease | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 2/3 | NCT02321397 | Nov 2014 → Mar 2016 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 347 trials | ||||||
| Phase 3 | NCT07017452 | Aug → Dec 2025 overdue | benign prostatic hyperplasia | University of Manitoba | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07323914 | Mar 2025 → Jan 2027 expected | Alzheimer disease | Xuanwu Hospital, Beijing | Recruiting | No outcome recorded |
| Phase 3 | NCT05081102 | Mar → May 2024 | — | Eurofarma Laboratorios S.A. | Completed | No outcome recorded |
| Phase 3 | NCT04808531 | Nov 2023 → Feb 2024 | — | Medlab Clinical | Unknown | No outcome recorded |
| Phase 3 | NCT05463809 | Jul 2022 → Jan 2023 | tenosynovitis of foot and ankle | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04429022 | Nov 2020 → May 2022 | — | State University of New York at Buffalo | Completed | No outcome recorded |
| Phase 3 | NCT04296396 | Sep 2020 → Apr 2022 | pregnancy disorder, substance-related disorder | The George Washington University Biostatistics Center | Completed | No outcome recorded |
| Phase 3 | NCT04246541 | Apr 2019 → Sep 2021 | musculoskeletal system disorder, substance-related disorder | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03586934 | Jun 2018 → Jun 2019 | substance-related disorder | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 3 | NCT03059238 | Sep 2016 → Mar 2019 | liver cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT02732262 | Apr 2016 → Jul 2018 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02603705 | Mar 2016 → Jun 2017 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02716857 | Mar 2016 → Aug 2017 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02240602 | Jul 2015 → Oct 2016 | — | Seoul National University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT02401750 | Jun → Jul 2015 | — | Elite Laboratories, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02084355 | Apr 2014 → Dec 2015 | cancer | Gyeongsang National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01918098 | Sep 2013 → Mar 2017 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02277678 | Aug 2013 → Dec 2014 | — | KK Women's and Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01885182 | Jun 2013 → Aug 2015 | cancer | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01685684 | Aug 2012 → Jun 2014 | chronic pain syndrome | Collegium Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01402375 | Jan 2012 → Nov 2014 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT01369615 | Oct 2011 → Dec 2013 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01451385 | Sep 2011 → Jun 2012 | osteoarthritis | Mallinckrodt | Completed | No outcome recorded |
| Phase 3 | NCT01427270 | Aug 2011 → Oct 2014 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01675635 | Jul 2011 → Jun 2012 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01358526 | May 2011 → Oct 2012 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01280331 | Jan → Apr 2011 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01675622 | Jan 2011 → Jun 2012 | cancer | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01428583 | Dec 2010 → May 2012 | chronic pain syndrome | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01192295 | Nov 2010 → Jul 2014 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01112644 | Apr 2010 → Jun 2011 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT01304134 | Mar → Aug 2010 | — | Mundipharma (China) Pharmaceutical Co. Ltd | Completed | No outcome recorded |
| Phase 3 | NCT01055015 | Feb → Dec 2010 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01167699 | Jun 2009 → Apr 2011 | — | Mundipharma Pharmaceuticals B.V. | Completed | No outcome recorded |
| Phase 3 | NCT03365817 | Feb 2009 → Dec 2014 | chronic pain syndrome, substance-related disorder | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 3 | NCT00813488 | Dec 2008 → Nov 2009 | chronic pain syndrome | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00771758 | Sep 2008 → Dec 2009 | — | Ortho-McNeil Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00626600 | May 2008 → May 2009 | — | Mundipharma Research Limited | Terminated | No outcome recorded |
| Phase 3 | NCT00560183 | Nov 2007 → Apr 2008 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00463047 | Jul 2007 → Feb 2009 | chronic pain syndrome | Cephalon | Completed | No outcome recorded |
| Phase 3 | NCT00412100 | Apr 2006 → Jul 2008 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT01559701 | Apr 2006 → Feb 2008 | — | Pain Therapeutics | Completed | No outcome recorded |
| Phase 3 | NCT00312221 | Apr 2004 → Jul 2005 | osteoarthritis | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00313014 | Feb 2004 → Sep 2005 | — | Purdue Pharma LP | Terminated | No outcome recorded |
| Phase 3 | NCT00092313 | Jun → Sep 2002 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00092326 | Jun → Sep 2002 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00399048 | ? → May 2001 | osteoarthritis, hip, osteoarthritis, knee | Alza Corporation | Completed | No outcome recorded |
| Phase 467 trials | ||||||
| Phase 4 | NCT07435077 | Aug → Dec 2026 expected | substance-related disorder | Wake Forest University Health Sciences | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07527039 | Apr 2026 → May 2028 expected | hypertrophy of breast | Carilion Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07326683 | Dec 2025 → Jan 2026 | — | Xin Chen | Completed | No outcome recorded |
| Phase 4 | NCT06897917 | Apr → Dec 2025 overdue | opioid-induced constipation | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06671002 | Jan 2025 → Oct 2026 expected | — | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT06731348 | Dec 2024 → Jul 2026 overdue | — | Walter Reed National Military Medical Center | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06444997 | Jun 2024 → Feb 2025 | — | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT07001709 | Apr 2024 → Dec 2025 overdue | prostate cancer | Deventer Ziekenhuis | Recruiting | No outcome recorded |
| Phase 4 | NCT06864312 | Oct 2023 → Jan 2025 | — | University College Cork | Completed | No outcome recorded |
| Phase 4 | NCT06041425 | Aug → Dec 2023 | hepatocellular carcinoma | The First Affiliated Hospital with Nanjing Medical University | Completed | No outcome recorded |
| Phase 4 | NCT05929937 | Jul 2023 → Jun 2027 expected | — | Clayton Petro | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05722002 | Feb 2023 → Dec 2026 expected | neuropathy, painful | University of Michigan | Recruiting | No outcome recorded |
| Phase 4 | NCT05602519 | Nov 2022 → May 2023 | — | Al-Azhar University | Completed | No outcome recorded |
| Phase 4 | NCT05598905 | Oct 2022 → Jan 2024 | respiratory underresponsiveness to hypoxia and hypercapnia | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05515822 | Oct 2022 → Apr 2024 | — | Qiang Fu | Unknown | No outcome recorded |
| Phase 4 | NCT06247488 | Jan 2022 → Apr 2023 | substance abuse | Arbor Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT05235503 | Dec 2021 → Dec 2022 | respiratory underresponsiveness to hypoxia and hypercapnia, substance-related disorder | Leiden University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04285853 | Sep 2020 → Sep 2022 | — | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT04522206 | Aug 2020 → Jun 2021 | vertebral column disorder | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT04396587 | May 2020 → Jan 2023 | substance-related disorder | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04177342 | Jan → Dec 2020 | achalasia | Chen Wannan | Unknown | No outcome recorded |
| Phase 4 | NCT05327777 | Nov 2019 → Jul 2021 | opioid abuse | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT03179475 | Sep 2019 → Nov 2021 | chronic pain syndrome | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT03783702 | Apr 2019 → Jul 2020 | drug dependence, opioid abuse, sinusitis | Stanford University | Completed | No outcome recorded |
| Phase 4 | NCT03685188 | Dec 2018 → Dec 2024 overdue | — | West China Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT03639415 | Oct 2018 → Oct 2020 | — | Fujian Cancer Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT03145272 | Oct 2018 → Aug 2020 | — | Mahidol University | Unknown | No outcome recorded |
| Phase 4 | NCT03549611 | Aug 2018 → Jun 2019 | nephrolithiasis | Kevin J Flynn MD | Withdrawn | No outcome recorded |
| Phase 4 | NCT03592485 | Jun → Aug 2018 | mitral valve disorder | Medical University of Lublin | Completed | No outcome recorded |
| Phase 4 | NCT03616639 | Jun → Dec 2018 | impaired renal function disease | Maastricht University Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT03588806 | May 2018 → Jul 2019 | chronic pain syndrome, substance-related disorder | Ajay Wasan, MD, Msc | Terminated | No outcome recorded |
| Phase 4 | NCT03510910 | Apr 2018 → Dec 2019 | — | NYU Langone Health | Completed | No outcome recorded |
| Phase 4 | NCT03415555 | Feb → Apr 2018 | mitral valve disorder | Medical University of Lublin | Completed | No outcome recorded |
| Phase 4 | NCT05363436 | Jan 2018 → Dec 2028 | opioid abuse | Thomas Jefferson University | Suspended | No outcome recorded |
| Phase 4 | NCT03121963 | Nov 2017 → Nov 2020 | — | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 4 | NCT03139240 | May 2017 → May 2018 | — | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 4 | NCT03019562 | Dec 2016 → Dec 2017 | — | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT03176121 | Oct 2016 → Dec 2018 | cancer | Taiwan Mundipharma Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02936934 | Oct → Dec 2016 | — | Hospital Civil de Guadalajara | Unknown | No outcome recorded |
| Phase 4 | NCT02741076 | Sep 2016 → Apr 2018 | opiate dependence, opioid abuse | Member Companies of the Opioid PMR Consortium | Terminated | No outcome recorded |
| Phase 4 | NCT02728648 | Apr 2016 → Nov 2017 | — | University of Malaya | Completed | No outcome recorded |
| Phase 4 | NCT02508935 | Nov 2015 → Apr 2017 | — | Mallinckrodt | Terminated | No outcome recorded |
| Phase 4 | NCT02660229 | Nov 2015 → Jul 2016 | — | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT02484352 | Jul → Oct 2015 | — | Yong-Hee Park | Completed | No outcome recorded |
| Phase 4 | NCT02452437 | May → Sep 2015 | chronic kidney disease | Emerio & Lourdes Linares Research and Education Center | Unknown | No outcome recorded |
| Phase 4 | NCT02573831 | Feb 2015 → Dec 2023 | — | Kuopio University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02573909 | Jan 2015 → Dec 2023 | neuropathy, painful | Kuopio University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02044497 | May 2014 → May 2027 expected | — | Boston Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02391844 | May 2014 → Dec 2015 | — | International Clinical Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01959204 | Oct 2013 → Aug 2019 | — | VistaPharm, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01675531 | Dec 2012 → Dec 2013 | cancer | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01719757 | Jul 2012 → Oct 2013 | cancer | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01536301 | Jun 2012 → Nov 2016 | osteoarthritis, hip | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02573922 | May 2012 → Dec 2014 | constipation disorder | Kuopio University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02238340 | Mar → Aug 2012 | — | Hospital Central Dr. Luis Ortega | Completed | No outcome recorded |
| Phase 4 | NCT01809106 | Apr 2011 → Oct 2014 | cancer | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 4 | NCT00964808 | Sep 2009 → May 2013 | neuropathy, painful | Vejle Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01115101 | Jul → Nov 2009 | — | Max Dieterich | Completed | No outcome recorded |
| Phase 4 | NCT00784810 | Feb 2009 → Mar 2010 | osteoarthritis | Napp Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 4 | NCT00681174 | Jul 2008 → Nov 2010 | — | University of Parma | Terminated | No outcome recorded |
| Phase 4 | NCT00480142 | Jul 2007 → Jul 2008 | hernia, double inguinal | Kaplan Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT00499460 | Nov 2006 → Aug 2008 | — | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 4 | NCT00369811 | Aug 2006 → Sep 2007 | — | Danish Pain Research Center | Completed | No outcome recorded |
| Phase 4 | NCT00271973 | Feb 2006 → Jan 2007 | — | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00260260 | Jun 2005 → Dec 2007 | — | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00378937 | Jan 2004 → Feb 2006 | cancer of unknown primary site | University Hospitals Bristol and Weston NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT00027014 | Sep 2001 → May 2005 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase not applicable28 trials | ||||||
| — | NCT07651722 | Jun → Sep 2026 expected | paralytic ileus | Tianjin First Central Hospital | Recruiting | No outcome recorded |
| — | NCT06721988 | Jan 2025 → Dec 2026 expected | chronic pain syndrome | Ailin Luo | Not yet recruiting | No outcome recorded |
| — | NCT06665048 | Dec 2024 → Dec 2025 overdue | — | Shantou University Medical College | Not yet recruiting | No outcome recorded |
| — | NCT06534801 | Sep 2024 → Jul 2025 overdue | — | Jianbo Wu | Not yet recruiting | No outcome recorded |
| — | NCT06517069 | May 2024 → Jun 2025 overdue | — | Yangzhou University | Recruiting | No outcome recorded |
| — | NCT06240390 | May → Aug 2024 | neuropathy, painful | Universidad Europea de Canarias | Withdrawn | No outcome recorded |
| — | NCT06276179 | Feb → Aug 2024 | — | Kafrelsheikh University | Unknown | No outcome recorded |
| — | NCT05795478 | Oct 2023 → Dec 2024 overdue | chronic pain syndrome | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| — | NCT05548582 | Jan 2023 → Dec 2026 expected | neuropathy, painful, opioid abuse | Johns Hopkins University | Active not recruiting | No outcome recorded |
| — | NCT05510986 | Oct 2022 → Oct 2024 | — | General Hospital of Ningxia Medical University | Unknown | No outcome recorded |
| — | NCT05142267 | Mar 2022 → Jul 2026 overdue | substance-related disorder | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| — | NCT06485817 | Nov 2021 → Apr 2022 | acute stress disorder, opioid abuse | University of Oslo | Completed | No outcome recorded |
| — | NCT04523623 | Jul 2020 → Jun 2021 | childhood acute lymphoblastic leukemia | Washington University School of Medicine | Withdrawn | No outcome recorded |
| — | NCT04295109 | Mar → Jul 2020 | adenomyosis, endometrial cancer, leiomyoma, uterine cervix neoplasm | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT05393414 | Nov 2019 → Mar 2020 | — | University of Puerto Rico | Completed | No outcome recorded |
| — | NCT03959969 | Jul → Dec 2019 | — | Medstar Health Research Institute | Completed | No outcome recorded |
| — | NCT04121416 | Apr → Aug 2019 | cardiovascular disorder | Shengjing Hospital | Completed | No outcome recorded |
| — | NCT04044820 | Mar 2019 → Dec 2026 expected | substance-related disorder | University Health Network, Toronto | Recruiting | No outcome recorded |
| — | NCT03024515 | Aug 2018 → Dec 2020 | — | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT04176783 | Mar 2018 → Jul 2021 | — | OrthoCarolina Research Institute, Inc. | Completed | No outcome recorded |
| — | NCT03478423 | Feb 2018 → Sep 2019 | — | Mount Sinai Hospital, Canada | Terminated | No outcome recorded |
| — | NCT03120962 | May 2017 → May 2020 | herpes zoster, postherpetic neuralgia | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT03045484 | May 2016 → May 2018 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT02455726 | Sep 2015 → Dec 2017 | peripheral arterial disease | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Unknown | No outcome recorded |
| — | NCT01016821 | Nov 2009 → Dec 2010 | — | Kuopio University Hospital | Completed | No outcome recorded |
| — | NCT00999544 | Oct 2009 → Apr 2011 | opioid abuse | Sharon Walsh | Completed | No outcome recorded |
| — | NCT00726830 | Mar 2009 → Sep 2010 | cancer of unknown primary site, central nervous system neoplasm, leukemia, lymphoproliferative syndrome +5 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT00337792 | Jun 2006 → Jul 2007 | — | Planned Parenthood League of Massachusetts | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 278 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT05761860 Comparator | Sep 2023 → Dec 2026 expected | — | University of Florida | Recruiting | No outcome recorded |
| Phase 0 | NCT04218409 Comparator | Sep 2021 → Dec 2026 expected | — | University of Florida | Recruiting | No outcome recorded |
| Phase 0 | NCT04612920 Background | Dec 2020 → Mar 2023 | — | University of Oklahoma | Completed | No outcome recorded |
| Phase 0 | NCT03845881 Comparator | Apr 2019 → Jul 2020 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT03837860 Comparator | Apr 2019 → Mar 2021 | opiate dependence, opioid abuse | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 0 | NCT03579446 Background | Nov 2018 → Jun 2023 | hematopoietic and lymphoid cell neoplasm, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT03612713 Comparator | Oct 2018 → Jun 2022 | opioid abuse | Yale University | Completed | No outcome recorded |
| Phase 133 trials | ||||||
| Phase 1 | NCT07218549 Comparator | May 2026 → Dec 2028 expected | substance-related disorder | Christopher D. Verrico | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06453265 Comparator | Jun → Nov 2024 | substance abuse | Tris Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05447286 Comparator | May 2023 → Dec 2024 | substance-related disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT05571345 Comparator | Oct → Dec 2022 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05470465 Background | Sep 2022 → Sep 2023 | respiratory underresponsiveness to hypoxia and hypercapnia | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT05491785 Comparator | Jul 2022 → Mar 2023 | — | Tris Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05567354 Comparator | Jun → Aug 2022 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT05256108 Comparator | Mar → Jul 2022 | substance abuse | Tris Pharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05043766 Comparator | Sep 2021 → Mar 2022 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04310579 Comparator | Jun 2020 → May 2021 | respiratory underresponsiveness to hypoxia and hypercapnia | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT05054868 Background | Apr 2020 → Jul 2024 | synostosis | Medstar Health Research Institute | Unknown | No outcome recorded |
| Phase 1 | NCT04112550 Comparator | Feb 2020 → Dec 2021 | intervertebral disk degenerative disorder, spondylolisthesis | The Methodist Hospital Research Institute | Unknown | No outcome recorded |
| Phase 1 | NCT03996694 Comparator | Jul → Oct 2019 | respiratory underresponsiveness to hypoxia and hypercapnia | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 1 | NCT03893175 Background | May 2019 → Mar 2022 | impacted teeth, multiple | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT03880487 Comparator | Mar 2019 → Apr 2020 | pain agnosia | Kalyra Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03765346 Comparator | Jul → Nov 2018 | substance abuse | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03747341 Background | Mar 2018 → Jan 2019 | substance-related disorder | Indivior Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04330547 Comparator | Feb 2018 → Feb 2019 | akinetic mutism, brain injury | University of Liege | Completed | No outcome recorded |
| Phase 1 | NCT03618589 Background | Nov 2016 → Dec 2019 | neuropathy, painful | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02454712 Comparator | Nov 2016 → Jan 2018 | — | Ensysce Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT03253133 Background | May 2016 → Oct 2020 | colorectal cancer | Institut du Cancer de Montpellier - Val d'Aurelle | Completed | No outcome recorded |
| Phase 1 | NCT02218021 Comparator | Aug → Nov 2014 | — | Alkermes, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02211625 Comparator | Jul → Oct 2014 | — | Trevena Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01986283 Comparator | Nov 2013 → Aug 2014 | substance-related disorder | Pain Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01825447 Comparator | Jul → Sep 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01746901 Comparator | Feb → Aug 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01775189 Comparator | Feb → Jul 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01677039 Comparator | Sep → Dec 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01568450 Comparator | Mar → Apr 2012 | — | GL Pharm Tech Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00801788 Comparator | Sep → Oct 2008 | — | Egalet Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00743587 Comparator | Sep 2008 → Mar 2009 | osteoarthritis, hand | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00853268 Comparator | Apr 2005 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00685295 Comparator | Aug 2008 → Feb 2009 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT07687966 Background | May → Jun 2026 overdue | — | Clarent Biopharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06505187 Background | Feb 2025 → Sep 2026 expected | — | University of Wisconsin, Madison | Recruiting | No outcome recorded |
| Phase 2 | NCT06232577 Background | Mar 2024 → May 2027 expected | — | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05842044 Background | Sep 2023 → Sep 2026 expected | renal carcinoma | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT03564548 Comparator | May 2021 → Mar 2022 | cancer | Tetra Bio-Pharma | Unknown | No outcome recorded |
| Phase 2 | NCT03978767 Background | Jun 2019 → Jun 2026 | severe pre-eclampsia | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03789318 Comparator | Dec 2018 → May 2019 | — | Concentric Analgesics | Completed | No outcome recorded |
| Phase 2 | NCT03426137 Comparator | Sep 2018 → Mar 2019 | substance-related disorder | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT03599089 Comparator | Jul → Oct 2018 | post-surgical hypoinsulinemia | Concentric Analgesics | Completed | No outcome recorded |
| Phase 2 | NCT03574792 Background | May 2018 → Apr 2021 | head and neck squamous cell carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT03389750 Comparator | Mar 2018 → Jun 2022 | substance-related disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT03173456 Comparator | Nov 2017 → Nov 2019 | musculoskeletal system disorder | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT03254459 Comparator | Sep → Nov 2017 | — | INSYS Therapeutics Inc | Completed | No outcome recorded |
| Phase 2 | NCT03088826 Comparator | Aug 2017 → Dec 2020 | — | Antonios Likourezos | Completed | No outcome recorded |
| Phase 2 | NCT03111186 Comparator | Apr 2017 → May 2019 | carpal tunnel syndrome, de Quervain disease, ganglion or cyst of synovium/tendon/bursa, palmar fibromatosis | University of Southern California | Completed | No outcome recorded |
| Phase 2 | NCT03415581 Comparator | Feb 2017 → Dec 2019 | opiate dependence | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 2 | NCT02862691 Comparator | Aug 2016 → Aug 2017 | — | Stony Brook University | Terminated | No outcome recorded |
| Phase 2 | NCT02934191 Background | Jun 2016 → Aug 2018 | tonsillitis | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT02309437 Comparator | Jan 2015 → Dec 2017 | nutritional disorder | Affiliated Cancer Hospital & Institute of Guangzhou Medical University | Completed | No outcome recorded |
| Phase 2 | NCT02307305 Background | Aug 2014 → Dec 2016 | neuropathy, painful | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01709214 Comparator | Dec 2012 → Apr 2014 | — | Tris Pharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01262560 Comparator | Feb 2012 → Feb 2014 | esophagitis, lung neoplasm | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01366014 Comparator | Jun 2011 → Jun 2012 | osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01197261 Comparator | Sep 2010 → Mar 2013 | interstitial cystitis | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2 | NCT01094262 Comparator | Apr 2010 → Jul 2011 | osteoarthritis, knee | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | No outcome recorded |
| Phase 2 | NCT00979953 Comparator | Oct 2009 → Apr 2010 | osteoarthritis, knee | Merck & Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00941304 Comparator | Aug → Nov 2009 | dental pulp disorder | BioDelivery Sciences International | Completed | No outcome recorded |
| Phase 2 | NCT00944697 Comparator | Jul 2009 → Mar 2010 | diabetic polyneuropathy | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2 | NCT00831051 Comparator | Dec 2008 → Jan 2009 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00699010 Comparator | Mar → Aug 2008 | opioid abuse | Acura Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00513656 Comparator | Sep 2007 → Mar 2010 | cancer, constipation disorder | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 2 | NCT00483977 Comparator | Jun → Dec 2007 | osteoarthritis | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00158184 Comparator | Jun 2004 → Jun 2009 | opioid abuse | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2/37 trials | ||||||
| Phase 2/3 | NCT07670507 Comparator | Jun → Dec 2026 expected | — | Albany Medical College | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07709598 Comparator | May → Oct 2026 expected | — | Shanghai Huilun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07699601 Comparator | May → Oct 2026 expected | — | Shanghai Huilun Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05597878 Comparator | Apr 2023 → Feb 2026 | prostate cancer, substance-related disorder | Wake Forest University Health Sciences | Terminated | No outcome recorded |
| Phase 2/3 | NCT04939987 Comparator | Aug → Oct 2022 | — | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT05389813 Comparator | Aug 2021 → Apr 2024 | — | An-Najah National University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03055507 Background | Apr → Dec 2017 | chronic rhinosinusitis | University of Washington | Completed | No outcome recorded |
| Phase 357 trials | ||||||
| Phase 3 | NCT07296770 Background | Oct 2026 → Dec 2027 expected | chronic pain syndrome | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07348627 Comparator | Mar 2026 → Aug 2028 expected | — | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT06973785 Comparator | Jul 2025 → Jun 2026 overdue | — | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06561035 Background | Sep 2024 → Aug 2025 overdue | — | Campbell Clinic | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06423703 Comparator | Jul 2024 → Jan 2025 | — | Tris Pharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05965492 Background | Jun 2024 → Jun 2025 | spinal cord disorder | University of Miami | Withdrawn | No outcome recorded |
| Phase 3 | NCT06381063 Background | Mar 2024 → Mar 2027 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT05831449 Background | May 2023 → Sep 2025 | toe, misshapen | Cali Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 3 | NCT05813847 Background | Apr 2023 → Sep 2025 | — | Cali Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 3 | NCT04813991 Comparator | Mar 2022 → Sep 2025 | — | Hackensack Meridian Health | Withdrawn | No outcome recorded |
| Phase 3 | NCT05161221 Comparator | Dec 2021 → Dec 2022 | neuropathy, painful | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT05154682 Comparator | Nov 2021 → Nov 2022 | neuropathy, painful | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04872270 Comparator | Apr 2021 → Apr 2022 | arthropathy | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04659317 Comparator | Dec 2020 → Dec 2028 expected | — | Emory University | Recruiting | No outcome recorded |
| Phase 3 | NCT04423107 Comparator | Jul 2020 → Jun 2022 | hypospadias | University of Oklahoma | Unknown | No outcome recorded |
| Phase 3 | NCT04872283 Comparator | May 2019 → Dec 2021 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT04246554 Background | May 2019 → Oct 2020 | — | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03823534 Background | Feb 2019 → Dec 2026 expected | bone neoplasm, plasma cell myeloma, substance-related disorder | St. Louis University | Recruiting | No outcome recorded |
| Phase 3 | NCT03480009 Background | Jul 2018 → Jun 2019 | — | Study Investigator-Sponsor | Completed | No outcome recorded |
| Phase 3 | NCT03584373 Comparator | Jul 2018 → Mar 2022 | nephrolithiasis | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT02929589 Background | Jul 2018 → Aug 2021 | — | Mike O'Callaghan Military Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT04872322 Comparator | Aug 2017 → Dec 2021 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT02892591 Comparator | Jun 2017 → Jun 2023 | spondylosis, cervical | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 3 | NCT03011905 Background | Jan 2017 → Apr 2019 | neuropathy, painful | Oslo University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02740114 Background | Aug 2016 → Jul 2020 | female reproductive organ cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 3 | NCT02601027 Background | Nov 2015 → Sep 2019 | female breast carcinoma | Stanford University | Completed | No outcome recorded |
| Phase 3 | NCT02604446 Comparator | Sep 2015 → Feb 2019 | arthritic joint disease | St. Olavs Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02391571 Comparator | Feb → Mar 2015 | substance withdrawal syndrome | Elite Laboratories, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02109640 Comparator | Oct 2014 → Aug 2015 | — | University of Edinburgh | Completed | No outcome recorded |
| Phase 3 | NCT01439100 Comparator | Oct 2011 → Aug 2013 | Parkinson disease | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT01438567 Comparator | Sep 2011 → Feb 2014 | constipation disorder | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT01427283 Comparator | Aug 2011 → Oct 2014 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 3 | NCT01165281 Comparator | Aug 2010 → Aug 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01179828 Comparator | Jul 2010 → Apr 2015 | — | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 3 | NCT01014559 Comparator | Feb 2010 → Jun 2011 | constipation disorder | Mundipharma SAS | Terminated | No outcome recorded |
| Phase 3 | NCT01063868 Comparator | Jan → Apr 2010 | diabetic polyneuropathy | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | No outcome recorded |
| Phase 3 | NCT01205126 Comparator | Dec 2009 → Feb 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT01016808 Comparator | Dec 2009 → Mar 2010 | — | QRxPharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00985621 Comparator | Oct 2009 → Dec 2010 | osteoarthritis | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00986180 Comparator | Sep 2009 → Dec 2010 | — | Ortho-McNeil Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01167127 Comparator | Jun 2009 → Apr 2011 | — | Mundipharma Pharmaceuticals B.V. | Completed | No outcome recorded |
| Phase 3 | NCT00902837 Comparator | May 2009 → Apr 2010 | osteoarthritis | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT00820027 Background | Dec 2008 → Dec 2010 | neuropathy, painful | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00822614 Comparator | Dec 2008 → Dec 2009 | — | Akela Pharma, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT00784472 Comparator | Dec 2008 → Jun 2012 | urolithiasis | Katja venborg Pedersen | Completed | No outcome recorded |
| Phase 3 | NCT00814580 Comparator | Dec 2008 → Mar 2010 | — | Ortho-McNeil Janssen Scientific Affairs, LLC | Completed | No outcome recorded |
| Phase 3 | NCT00784277 Comparator | Oct 2008 → Jul 2009 | osteoarthritis | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00613938 Comparator | Feb → Oct 2008 | arthropathy, toe, misshapen | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00654069 Comparator | Sep 2007 → Feb 2008 | — | Acura Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00486811 Comparator | Jun 2007 → Jul 2008 | osteoarthritis, knee | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00449176 Comparator | Feb 2007 → May 2008 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00421928 Comparator | Jan 2007 → Jul 2008 | osteoarthritis, knee | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00361504 Comparator | Nov 2006 → Jul 2008 | osteoarthritis, hip, osteoarthritis, knee | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00364533 Comparator | Oct 2006 → Dec 2007 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Terminated | No outcome recorded |
| Phase 3 | NCT00261495 Comparator | Mar 2006 → Apr 2008 | — | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 3 | NCT01971632 Comparator | Jan 2005 → May 2006 | — | Mundipharma Research GmbH & Co KG | Completed | No outcome recorded |
| Phase 3 | NCT00315445 Comparator | Dec 1997 → May 1998 | — | Purdue Pharma LP | Completed | No outcome recorded |
| Phase 4100 trials | ||||||
| Phase 4 | NCT07600697 Comparator | Jul 2026 → Jul 2027 expected | female stress incontinence, pelvic organ prolapse | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07219888 Comparator | Feb → Dec 2026 expected | osteoarthritis, knee | University of Louisville | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07153003 Comparator | Feb 2026 → Sep 2030 expected | — | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07355166 Background | Feb → Jul 2026 overdue | — | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07434427 Comparator | Feb 2026 → May 2027 expected | chronic pain syndrome | Medical University of Silesia | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07076069 Background | Jul 2025 → Jun 2028 expected | rotator cuff syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT06113211 Comparator | Oct 2024 → Sep 2026 expected | disease of bone structure, substance-related disorder | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 4 | NCT06669650 Comparator | Sep 2024 → Dec 2025 overdue | opiate dependence | University of Tennessee Graduate School of Medicine | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02703610 Comparator | Jul 2024 → Jul 2026 | — | Albany Medical College | Withdrawn | No outcome recorded |
| Phase 4 | NCT06484192 Comparator | Jun 2024 → Jun 2025 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 4 | NCT06434233 Comparator | Apr 2024 → Nov 2026 expected | female infertility, substance-related disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 4 | NCT06186141 Comparator | Mar 2024 → Dec 2027 expected | — | Murdoch Childrens Research Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06691633 Comparator | Feb → Sep 2024 | osteoarthritis, knee | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT05821517 Comparator | Dec 2023 → Dec 2026 expected | — | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 4 | NCT05988710 Comparator | Oct 2023 → Jan 2028 expected | opioid abuse, pain agnosia | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05974501 Background | Sep 2023 → Jan 2024 | osteoarthritis, knee | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT06042426 Comparator | Sep 2023 → Feb 2024 | osteoarthritis, knee | University of Puerto Rico | Unknown | No outcome recorded |
| Phase 4 | NCT05820685 Background | Jul 2023 → Apr 2024 | nervous system injury | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 4 | NCT05924165 Comparator | May 2023 → Jan 2025 | nephrolithiasis | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT05974423 Comparator | Dec 2022 → Dec 2024 | substance-related disorder | The Cooper Health System | Unknown | No outcome recorded |
| Phase 4 | NCT05639712 Comparator | Dec 2022 → May 2025 | substance-related disorder | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05488847 Comparator | Jun 2022 → Dec 2024 overdue | arthropathy | Henry Ford Health System | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05076110 Comparator | Apr 2022 → Oct 2025 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT05231460 Comparator | Feb 2022 → Jun 2026 overdue | neuropathy, painful | University of Arizona | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05053126 Comparator | Jul 2021 → Apr 2022 | substance abuse | Viatris Specialty LLC | Completed | No outcome recorded |
| Phase 4 | NCT05319756 Comparator | Apr → Dec 2021 | substance abuse | Viatris Specialty LLC | Completed | No outcome recorded |
| Phase 4 | NCT04761302 Comparator | Apr 2021 → Oct 2022 | — | University of Puerto Rico | Completed | No outcome recorded |
| Phase 4 | NCT04541147 Background | Apr 2021 → Dec 2023 | neuropathy, painful | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT04726878 Background | Feb → Aug 2021 | breast cancer | Medical University of Lublin | Completed | No outcome recorded |
| Phase 4 | NCT04240626 Background | Jan 2021 → Jun 2026 overdue | morbid obesity | University of California, Davis | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05468671 Background | Jan → Aug 2021 | bronchial neoplasm | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05360433 Comparator | Nov 2020 → Dec 2022 | — | Carilion Clinic | Unknown | No outcome recorded |
| Phase 4 | NCT04122443 Comparator | Dec 2019 → Jul 2022 | musculoskeletal system disorder | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04149964 Background | Nov 2019 → Sep 2022 | — | Corewell Health East | Completed | No outcome recorded |
| Phase 4 | NCT04246697 Background | Nov 2019 → Jun 2021 | head and neck cancer | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03987022 Comparator | Aug 2019 → Apr 2022 | — | MetroHealth Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04015908 Background | Aug 2019 → Jan 2023 | substance-related disorder | University of Utah | Completed | No outcome recorded |
| Phase 4 | NCT03054831 Comparator | Jul 2019 → Dec 2026 expected | — | Boston Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04132011 Comparator | May 2019 → Mar 2020 | chronic pain syndrome | University Health Network, Toronto | Withdrawn | No outcome recorded |
| Phase 4 | NCT03859024 Background | Mar 2019 → Apr 2023 | urethral stricture | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT03759028 Comparator | Feb 2019 → Dec 2027 expected | — | University of California, Los Angeles | Recruiting | No outcome recorded |
| Phase 4 | NCT03738904 Background | Oct 2018 → Aug 2022 | anus disorder | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03545893 Comparator | Jun 2018 → Feb 2019 | — | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT03472469 Comparator | Apr 2018 → Jul 2019 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03454217 Comparator | Mar 2018 → Sep 2020 | sleep apnea syndrome | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 4 | NCT03314792 Comparator | Dec 2017 → Feb 2019 | uterine disorder | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02160301 Background | Nov 2017 → Dec 2019 | — | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded |
| Phase 4 | NCT03888144 Comparator | Oct 2017 → Aug 2021 | nephrolithiasis, ureterolithiasis | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT04110665 Comparator | Sep 2017 → Sep 2019 | disease of the tendon | Nîmes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02932579 Background | Jul 2017 → Jan 2021 | — | University of Rochester | Terminated | No outcome recorded |
| Phase 4 | NCT03202550 Comparator | Jun 2017 → May 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT03052816 Comparator | Apr 2017 → Jun 2018 | pelvic organ prolapse | University Hospitals Cleveland Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04399122 Comparator | Mar 2017 → Oct 2019 | — | 59th Medical Wing | Completed | No outcome recorded |
| Phase 4 | NCT02994173 Comparator | Feb 2017 → Nov 2019 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02009306 Background | Jan 2017 → Feb 2018 | — | Gloucestershire Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT02987920 Background | Jan 2017 → Jan 2018 | — | University of Southern California | Terminated | No outcome recorded |
| Phase 4 | NCT03176199 Comparator | Sep 2016 → Dec 2018 | cancer | Taiwan Mundipharma Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT02519023 Background | Jul 2016 → May 2017 | — | University of Minnesota | Completed | No outcome recorded |
| Phase 4 | NCT02678897 Comparator | Mar 2016 → Aug 2018 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06142591 Comparator | Jan 2016 → Feb 2018 | — | Poznan University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02358850 Comparator | Jan 2016 → Jan 2019 | neuropathy, painful | University of Nebraska | Terminated | No outcome recorded |
| Phase 4 | NCT02604550 Comparator | Nov 2015 → Apr 2016 | — | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02516059 Comparator | Sep 2015 → Feb 2017 | urinary bladder cancer | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT02464813 Comparator | Aug 2015 → Aug 2018 | scoliosis, spondylolisthesis | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02455518 Comparator | Jul 2015 → Aug 2016 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02454881 Comparator | Jun 2015 → Oct 2019 | neuropathy, painful | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02426463 Comparator | Apr 2015 → Feb 2017 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02449369 Comparator | Apr 2015 → Sep 2016 | — | AdventHealth | Completed | No outcome recorded |
| Phase 4 | NCT02361567 Comparator | Apr 2015 → Mar 2016 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 4 | NCT02219581 Background | Oct 2014 → Dec 2015 | osteoarthritis | Thomas L Bradbury | Terminated | No outcome recorded |
| Phase 4 | NCT02101476 Comparator | May → Aug 2014 | — | Lotus Clinical Research, LLC | Completed | No outcome recorded |
| Phase 4 | NCT02110719 Comparator | Mar 2014 → Jul 2015 | constipation disorder | Hartford Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02101840 Comparator | Feb → Dec 2014 | substance-related disorder | Centre for Addiction and Mental Health | Completed | No outcome recorded |
| Phase 4 | NCT02032927 Comparator | Jun 2013 → Jun 2015 | chronic pain syndrome | Fondazione IRCCS Policlinico San Matteo di Pavia | Withdrawn | No outcome recorded |
| Phase 4 | NCT01838616 Comparator | Apr 2013 → Jan 2014 | neuropathy, painful | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 4 | NCT02571881 Comparator | Oct 2012 → Dec 2023 | constipation disorder, neuropathy, painful | Kuopio University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02295124 Comparator | Aug 2012 → Jan 2016 | — | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT01672112 Comparator | Jul 2012 → Jan 2015 | — | Tan Tock Seng Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01587274 Comparator | Apr 2012 → Oct 2014 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01458015 Comparator | Oct 2011 → Nov 2013 | peripheral neuropathy | University Hospital Schleswig-Holstein | Terminated | No outcome recorded |
| Phase 4 | NCT01816581 Comparator | Jul 2011 → May 2012 | postoperative ventricular dysfunction | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01374763 Comparator | Jul → Dec 2011 | — | Kati Järvelä | Completed | No outcome recorded |
| Phase 4 | NCT01313780 Comparator | May 2011 → Oct 2013 | cancer | Mundipharma Korea Ltd | Completed | No outcome recorded |
| Phase 4 | NCT01500317 Comparator | May → Oct 2011 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01344720 Comparator | May 2011 | — | Azienda Sanitaria Locale 4, Teramo | Unknown | No outcome recorded |
| Phase 4 | NCT03105518 Background | Mar 2011 → Jun 2023 | — | Brigham and Women's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01381120 Background | Oct 2010 → Jun 2012 | overactive bladder | Barrie Urology Associates | Completed | No outcome recorded |
| Phase 4 | NCT01267825 Comparator | Sep 2010 → Aug 2013 | lumbar disk disease, radiculopathy | Montefiore Medical Center | Terminated | No outcome recorded |
| Phase 4 | NCT01109511 Comparator | Mar 2010 → Jun 2011 | opioid-induced constipation | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01162304 Comparator | Mar 2010 → Dec 2013 | chronic pain syndrome | University of Rochester | Terminated | No outcome recorded |
| Phase 4 | NCT01083485 Comparator | Mar → Oct 2010 | — | Mundipharma Oy | Completed | No outcome recorded |
| Phase 4 | NCT00955110 Comparator | Jun → Sep 2009 | — | Endo USA Inc., a Keenova Therapeutics Company | Completed | No outcome recorded |
| Phase 4 | NCT02479165 Comparator | May 2009 → Sep 2010 | impaired renal function disease, myocardial infarction | Aalborg University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01502644 Comparator | Feb 2009 → Jan 2013 | anxiety, chronic pain syndrome, depressive disorder, intervertebral disk degenerative disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00916890 Comparator | Feb 2009 → Feb 2015 | chronic pain syndrome | Fondazione IRCCS Policlinico San Matteo di Pavia | Suspended | No outcome recorded |
| Phase 4 | NCT00484718 Comparator | Jan 2008 → Jun 2009 | osteoarthritis, knee | Pfizer | Terminated | No outcome recorded |
| Phase 4 | NCT02152592 Comparator | Oct 2007 → Mar 2009 | — | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00528177 Comparator | Sep 2007 → Jun 2008 | leiomyoma | Ullevaal University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00254631 Comparator | Apr 2007 → Dec 2008 | — | Rambam Health Care Campus | Completed | No outcome recorded |
| Phase 4 | NCT00414453 Comparator | Jan 2007 → Aug 2011 | chronic pain syndrome, multiple sclerosis, neuropathy, painful | University of Rochester | Terminated | No outcome recorded |
| Phase not applicable40 trials | ||||||
| — | NCT07307495 Background | Jan 2026 → Jul 2027 expected | — | Xijing Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07154433 Comparator | Sep 2025 → May 2026 | osteochondritis dissecans | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT07095569 Comparator | Aug 2025 → Aug 2026 overdue | breast cancer | National Cancer Institute, Egypt | Recruiting | No outcome recorded |
| — | NCT07097038 Comparator | Jul → Dec 2025 overdue | — | Henan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06917118 Comparator | May → Nov 2025 overdue | — | University of Puerto Rico | Not yet recruiting | No outcome recorded |
| — | NCT06338865 Background | May 2024 → Apr 2027 expected | — | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| — | NCT06390046 Background | Apr → Dec 2024 | — | Jagiellonian University | Completed | No outcome recorded |
| — | NCT05731973 Background | Dec 2023 → Apr 2025 | pectus excavatum | Zuyderland Medical Center | Completed | No outcome recorded |
| — | NCT06003218 Background | Oct 2023 → Sep 2024 | liver cancer | Peking University First Hospital | Completed | No outcome recorded |
| — | NCT04194528 Background | Jan → Sep 2020 | metastatic malignant neoplasm | SWOG Cancer Research Network | Terminated | No outcome recorded |
| — | NCT03023462 Comparator | Sep 2019 → Jun 2020 | — | Ostfold Hospital Trust | Completed | No outcome recorded |
| — | NCT04025606 Background | Jun 2019 → Dec 2022 | lung cancer | St. Olavs Hospital | Completed | No outcome recorded |
| — | NCT03756961 Comparator | May 2019 → May 2028 expected | obesity disorder | Göteborg University | Recruiting | No outcome recorded |
| — | NCT04278703 Comparator | Feb 2019 → Jan 2021 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| — | NCT03755609 Comparator | Jun 2018 → Jan 2019 | — | Changhai Hospital | Unknown | No outcome recorded |
| — | NCT03529201 Background | May 2018 → Feb 2019 | chronic pain syndrome, neuropathy, painful | Medical University of Lublin | Completed | No outcome recorded |
| — | NCT03351439 Background | Apr 2018 → Sep 2021 | chronic pain syndrome | Western University, Canada | Completed | No outcome recorded |
| — | NCT04003350 Background | Dec 2017 → Nov 2018 | osteoarthritis, knee | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| — | NCT04448457 Comparator | Sep 2017 → Jul 2018 | — | Centre Hospitalier Universitaire de Tivoli | Completed | No outcome recorded |
| — | NCT03358888 Comparator | Jun 2017 → Jan 2018 | osteoarthritis, hip | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| — | NCT03597308 Comparator | Mar → Jul 2017 | — | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| — | NCT03204045 Comparator | Feb → May 2017 | — | Yeungnam University College of Medicine | Completed | No outcome recorded |
| — | NCT02826551 Background | Jan → May 2017 | — | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| — | NCT03364088 Comparator | Oct 2016 → Dec 2018 | chronic pain syndrome, osteoarthritis, knee, rheumatoid arthritis | Riku Antero Palanne | Completed | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02600247 Background | Nov 2015 → Nov 2016 | osteoarthritis | The Catholic University of Korea | Unknown | No outcome recorded |
| — | NCT02440399 Background | Jul 2015 → May 2017 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT02132416 Comparator | May 2014 → Jun 2017 | — | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT02136784 Comparator | Apr → Dec 2014 | — | University of California, Los Angeles | Unknown | No outcome recorded |
| — | NCT02094807 Background | Apr 2014 → May 2020 | — | Sahlgrenska University Hospital | Withdrawn | No outcome recorded |
| — | NCT01939379 Comparator | Sep 2013 → Jul 2017 | — | Loma Linda University | Withdrawn | No outcome recorded |
| — | NCT02840526 Background | May 2013 → Dec 2014 | — | Silesian University of Medicine | Completed | No outcome recorded |
| — | NCT01764048 Background | Nov 2012 → Jan 2014 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01268670 Comparator | Jul 2012 → Jul 2013 | — | Children's Hospitals and Clinics of Minnesota | Suspended | No outcome recorded |
| — | NCT01859715 Comparator | Jun 2012 → Jan 2013 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT03435692 Background | Jul 2011 → Jul 2014 | — | Seattle Children's Hospital | Terminated | No outcome recorded |
| — | NCT00733083 Comparator | Sep 2008 → Dec 2009 | — | University of Turku | Unknown | No outcome recorded |
| — | NCT01328782 Comparator | Jun 2008 → Aug 2010 | — | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT00600405 Background | Aug 2006 → Nov 2007 | nephrolithiasis, ureterolithiasis | MaineHealth | Completed | No outcome recorded |
| — | NCT02293525 Comparator | ? → Jan 2016 | — | Vital 5, LLC | Withdrawn | No outcome recorded |
Press releases naming this drug 13 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-09-12 | Daiichi Sankyo | Daiichi Sankyo Announces Launch of Oxycodone Extended Release Tablets NX “Daiichi Sankyo” for Sustained Cancer Pain Treatment in Japan daiichisankyo.com ↗ |
| 2017-05-31 | Daiichi Sankyo | Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce Plans for Commercialization of RoxyBond™ (oxycodone hydrochloride) Tablets CII in the U.S. daiichisankyo.com ↗ |
| 2017-03-08 | Daiichi Sankyo | Daiichi Sankyo Announces New Oxycodone Extended Release Tablets "Daiichi Sankyo" for Sustained Cancer Pain Treatment daiichisankyo.com ↗ |
| 2016-08-19 | Pfizer | FDA Approves TROXYCA® ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain pfizer.com ↗ |
| 2016-06-08 | Pfizer | Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval pfizer.com ↗ |
| 2015-02-13 | Pfizer | Pfizer Announces FDA Acceptance for Review of a New Drug Application for ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) pfizer.com ↗ |
| 2007-03-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva To Sell Oxycodone Through The End Of 2007 tevapharm.com ↗ |
| 2006-10-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Oxycontin® Litigation Dismissed; Settlement With Purdue Finalized tevapharm.com ↗ |
| 2006-08-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Settlement Of Oxycontin® Litigation tevapharm.com ↗ |
| 2005-12-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Final Approval of Oxycodone ER Tablets, 10 Mg, 20 Mg and 40 Mg tevapharm.com ↗ |
| 2004-12-10 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Oxycodone Hydrochloride Er Tablets, 10 Mg, 20 Mg, And 40 Mg tevapharm.com ↗ |
| 2004-03-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Initiates Commercialization of Oxycodone 80 Mg tevapharm.com ↗ |
| 2003-09-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval Of Oxycodone Hydrochloride ER Tablets, 80 Mg tevapharm.com ↗ |
Evidence & citations 90 cited values
Every value below carries the sentence it was read from. 501 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxycodone | “The objectives of this study are to assess pharmacokinetics of oxycodone and naloxone from oxycodone/naloxone (OXN) prolonged release (PR) tablet 5/2.5 mg (OXN 5/2.5) and 20/10...” NCT02880475 ↗454“A Double-blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety, of Oxycodone Immediate-release Capsules Versus Morphine Immediate-release Tablets in...” NCT01675635 ↗ “Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or...” NCT03317730 ↗ “The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under...” NCT05485012 ↗ “If patient weight \<100 kg, oxycodone 5 mg tab PO q6h PRN for pain score 8-10 will be prescribed; disp-10, no refill. If patient weight \>100 kg, oxycodone 10 mg tab PO q6h PRN...” NCT07527039 ↗ “A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in...” NCT00399048 ↗ “OBJECTIVE: To evaluate the efficacy and safety of two dose strengths of oxycodone hydrochloride (HCl)/niacin tablets * for the treatment of moderate-to-severe postoperative...” PMID 21231862 ↗ Jan 2011 “This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of...” NCT05265052 ↗ “Participants who belong to the experimental arm will be given a single 'per os' dose of percocet (325mg acetaminophen + 7.5mg oxycodone) and lorazepam 1 mg, 30 minutes prior to...” NCT07017452 ↗ “ALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride (HCl), an opioid agonist, surrounding sequestered naltrexone HCl, an...” PMID 25724154 ↗ Apr 2015 “Patients will receive conservative treatment Acetaminophen (paracetamol) 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.” NCT07095569 ↗ “Acetaminophen 975mg every 4 hours, Meloxicam 7.5mg once per day, Pregabalin 50mg twice per day, Magnesium 400mg once per day, along with rescue Oxycodone 5mg every 4 hours, as needed” NCT07076069 ↗ “In fentanyl group (36 patients), 50 ug of fentanyl, and in oxycodone group, 4 mg of oxycodone will be administered 20 minutes before the end of the surgery, in triple blind manner.” NCT05602519 ↗ “This study aimed to investigate the effect of the equivalent doses of fentanyl, oxycodone, and butorphanol on bowel function in patients undergoing laparoscopic hysterectomy.” PMID 35209847 ↗ Feb 2022 “The specific parameters are a loading dose: 0.03 mg/kg of Oxycodone diluted with saline to 3 ml, administered 20-30 minutes before the end of surgery.” NCT07307495 ↗ “Subjects will receive oral oxycodone as needed for pain which will be titrated weekly based on pain response, adverse effects, and patient preference.” NCT06837857 ↗ “oral Targin (a combination of oxycodone-hydrochloride and the opioid antagonist naloxone hydrochloride-dihydrate) or patient-controlled IV morphine” PMID 24375220 ↗ Dec 2013 “Tylenol (compound oxycodone/acetaminophen) is a non-narcotic analgesic that combines a lower dose of oxycodone (5 mg) with acetaminophen (325 mg).” NCT07323914 ↗ “Oxycodone is a semi-synthetic narcotic analgesic and historically has been a popular drug of abuse among the narcotic abusing population.” NCT06276179 ↗ “If pain is uncontrolled, patients will also be sent home with a prescription with 10 pills of 5 mg of Oxycodone for breakthrough pain.” NCT06113211 ↗ “Oxycodone solution or tablet (depending on age of patient) at 0.05-0.1 mg/kg/dose every 6hrs; max 5mg (obese/OSA); prescribe 30 doses” NCT04541147 ↗ “COV795 is a multilayer extended-release tablet for oral administration of oxycodone hydrochloride (15 mg) and acetaminophen (650 mg)” NCT01451385 ↗ “Participants will take 5 mg/325 mg of oxycodone - acetaminophen every 6 hours as needed for pain, with a maximum of 4 doses per day.” NCT07154433 ↗ “comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies” NCT03024515 ↗ “Patients will receive a prescription of 5 tablets of opioids (preferred: Oxycodone, or surgeon preference for Oxycodone intolerance)” NCT05929937 ↗ “1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days” NCT02929589 ↗ “Participants will receive standard opioid prescribing - Oxycodone HCl 5mg x10 tablets for major cases, 5 tablets for minor cases.” NCT06731348 ↗ “Oxycodone/acetaminophen (Percocet) 5 mg/325 mg as needed for breakthrough pain for patients in Percocet+ Acetaminophen group.” NCT03510910 ↗ “* Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid” NCT02219581 ↗ “Oxycodone NCA or in the form of oral tablets [naloxone (naloxone hydrochloride) + oxycodone (oxycodone hydrochloride)]” NCT06390046 ↗ “One group will receive oxycodone (standard of care) + CBP-0276 at a dose of 600 mg, orally once daily for 28 days.” NCT07687966 ↗ “At t = 0, the subject will ingest 1 oxycodone 20 mg immediate release or a placebo capsule with 100 mL water.” NCT05235503 ↗ “Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.” NCT03618589 ↗ “Rescue medication: TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)as necessary up to 4 times per day.” NCT01764048 ↗ “XARTEMIS XR [7.5 mg oxycodone hydrochloride and 325 mg acetaminophen (APAP)] Extended-Release Tablets” NCT02508935 ↗ “Oxycodone 0.1 mg/kg (maximum 5 mg) by mouth every 4 to 6 hours as needed for pain, number 10 doses.” NCT06671002 ↗ “oxycodone combined with acetaminophen (2.5 mg / 325 mg) two tabs PO every six hours up to 72 hours” NCT05393414 ↗ “Single 15 mL dose of oral solution of OC/APAP (total dose 15 mg oxycodone/975 mg acetaminophen)” NCT02966860 ↗ “medications in the opioid family such as Hydromorphone, Hydrocodone, Tramadol, or Oxycodone.” NCT04176783 ↗ “Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone)” NCT03472469 ↗ “Gabapentin and oxycodone are commonly used in combination for the treatment of chronic pain.” NCT04315181 ↗ “Oxycodone 5mg 1-2 tablets every 4 hours as needed for pain. 30 tablets will be provided.” NCT03805386 ↗ “5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.” NCT00315445 ↗ “8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses” NCT01030406 ↗ “In addition per-oral painkillers (oxycodone and paracetamol) from the day of surgery.” NCT04025606 ↗ “Multi-modal with as needed oxycodone and tramadol provided for break-through pain” NCT03358888 ↗ “* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses” NCT05722002 ↗ “either oral ketorolac (experimental group) or oral oxycodone (control group)” NCT06973785 ↗ “10. 5 tablets of oxycodone 5mg as needed for severe breakthrough pain only.” NCT06561035 ↗ “25 tablets of 5mg of oxycodone for rescue pain control postoperatively.” NCT07355166 ↗ “Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine” NCT02033707 ↗ “Controlled Release oxycodone 10 mg orally twice a day for 24 hours” NCT02152592 ↗ “Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed.” NCT01262560 ↗ “1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage” NCT04676802 ↗ “4. Oxycodone oral 5 mg PRN every 6 hours (#30, refill #0)” NCT03738904 ↗ “1 mgml-1 concentration oxycodone solution intravenously” NCT02840526 ↗ “PO Oxycodone 5mg, 10mg q4h for moderate and severe pain” NCT05231460 ↗ “Against severe pain patients get Opiates (oxycodone).” NCT02678897 ↗ “PTI-821 (oxycodone) 40 mg extended release capsule” NCT03475862 ↗ “Morphine, oxycodone, metadone, fentanyl, tramadol” NCT03365817 ↗ “Level 3: Oxycodone 5mg, Morphine sulfate 10mg.” NCT04330547 ↗ “Long-term Safety of PF-00345439 (Oxycodone)” NCT01559701 ↗ “Oxycodone (OxyContin®, OxyIR®, Roxicodone®)” NCT06240390 ↗ “ * Diamorphine * Oxycodone * Fentanyl” NCT02009306 ↗ “Oxycodone 5mg every 6 hours prn for pain” NCT03640247 ↗ “Intravenous Challenge Drug: Oxycodone” NCT03389750 ↗ “Naproxen + Oxycodone/ Acetaminophen” NCT01267825 ↗ “Oxycodone/APAP(acetaminophen)” NCT02101476 ↗ “Oxycodone controlled release” NCT04132011 ↗ “Targin (Oxycodone/Naloxone)” NCT01675531 ↗ “Oxycodone 5mg PO q4-6h PRN” NCT04044820 ↗ “Oxycodone Hydrochloride” NCT07296770 ↗ “Oxycodone HCl IR 40 mg” NCT06453265 ↗ “Oxycodone HCl 20mg” NCT01779492 ↗ “Drug: Oxycodone” NCT02165930 ↗ “Drug: Oxycodone” NCT03105518 ↗ “Oxycodone 10mg” NCT03549611 ↗ “Oxycodone” NCT00864357 ↗ “Oxycodone” NCT00822614 ↗ “oxycodone” NCT03023462 ↗ “oxycodone” NCT05463367 ↗ “Oxycodone” NCT02132416 ↗ “Oxycodone” NCT03987022 ↗ “Oxycodone” NCT02094807 ↗ “Oxycodone” NCT03705559 ↗ |
| Known as | (-)-14-hydroxydihydrocodeinone | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Abtard | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Anhydrous oxycodone hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Apo-Oxycodone CR | “a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®” NCT02101840 ↗ |
| Known as | Candox | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Carexil | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | controlled-release (CR) oxycodone | “AIMS: The efficacy and safety of monotherapy with fulranumab, a monoclonal antibody that neutralises human nerve growth factor (NGF), was evaluated compared with placebo and an...” PMID 27238963 ↗ Jun 2016 |
| Known as | CR Oxycodone | “The common adverse event of Controlled-Release Oxycodone(CR Oxycodone ) are nausea (29.9%)、constipation （25.4%）、dizziness（22.4%） and vomit（11.9%）” NCT03639415 ↗ |
| Known as | Dihydrone | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Dolocodon pr | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Endocodone | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Fentanyl (as Citrate) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06435949 ↗ |
| Known as | GL2907 XL | “GL2907 XL 20mg (Oxycodone 20mg, fasted)” NCT01568450 ↗ |
| Known as | IDS-NO-002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Ircodon | “Drug generic names: celecoxib (celebrex), Pregabalin (Lyrica), acetaminophen/tramadol (ultracet ER), oxycodone (Ircodon)” NCT02600247 ↗ |
| Known as | IRO-A | “An immediate-release oxycodone hydrochloride formulation (IRO-A) indicated for moderate to severe pain was designed (by adding functional excipients) to discourage tampering...” PMID 22717418 ↗ Jun 2012 |
| Known as | Leveraxo | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Longtec | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Lynlor | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | N02AA05 | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | NSC-19043 | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | OC-CR | “OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR).” PMID 21102969 ↗ Nov 2010 |
| Known as | ORF | “Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours” NCT01160614 ↗ |
| Known as | Oxaydo | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxecta | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxeltra | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxicodona | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxicone | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | OXY PR | “Subjects with moderate to severe pain due to osteoarthritis (OA) will be randomised to oxycodone/naloxone prolonged release (OXN PR) or oxycodone prolonged release tablets...” NCT00902837 ↗4“compared with oxycodone prolonged-release tablets (OxyPR) in patients with moderate/severe cancer pain.” PMID 21937568 ↗ Sep 2011 “Oxycodone 10 or 20 mg Prolonged Release Tablets (OXY PR)” NCT01083485 ↗ “prolonged-release oxycodone (OXY PR, N = 115)” PMID 32020565 ↗ Feb 2020 |
| Known as | oxycodon | “If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po.” NCT02678897 ↗ |
| Known as | Oxycodone cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | oxycodone controlled release | “OBJECTIVE: To compare cognitive and psychomotor effects of oxymorphone extended release (OM-ER) versus oxycodone controlled release (OC-CR).” PMID 21102969 ↗ Nov 2010 |
| Known as | Oxycodone CR | “The purpose of this study is to compare the subjective and objective effects of Oxymorphone ER (Opana ER) versus Oxycodone CR (Oxycontin).” NCT00955110 ↗3“Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.” NCT01165281 ↗ |
| Known as | Oxycodone HCI | “A Randomized, Repeated- Dose, Parallel-Group Comparison of Safety, Efficacy, and Quality of Life Measures With Dilaudid CR (Hydromorphone HCI) or Oxycontin (Oxycodone HCI) in...” NCT00399048 ↗ |
| Known as | Oxycodone HCl | “A total of 606 patients aged ≥18 years with moderate-to-severe pain post-bunionectomy were screened, and 405 patients were randomized to receive placebo, 2 × 5/30 mg oxycodone...” PMID 21231862 ↗ Jan 201116“A Phase 4 Randomized Double-Blind Double-Dummy Placebo & Active-Controlled Single-Dose Six-Way Crossover Study Evaluating the Abuse Potential of Lyrica® Taken Orally With...” NCT05053126 ↗ “tapentadol ER (100-250 mg bid) has been shown to provide comparable pain relief to oxycodone HCl CR (20 - 50 mg bid) for chronic osteoarthritis knee pain and low back pain over...” PMID 23340531 ↗ Jan 2013 “Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.” NCT01192295 ↗ “Participants will receive a single oral dose of oxycodone HCl 20 mg and a placebo that looks like gabapentin” NCT05319756 ↗ “Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours” NCT01427283 ↗ “Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours” NCT01427270 ↗ “Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).” NCT00313014 ↗ “Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.” NCT01825447 ↗ “oxycodone HCl and naltrexone HCl extended-release capsules” NCT01428583 ↗ “oxycodone HCl controlled release (CR; 20-50 mg)” PMID 24353047 ↗ Sep 2013 “Oxycodone HCl controlled-release” NCT01369615 ↗ “oxycodone HCl 40 mg alone” NCT00699010 ↗ “Drug: Oxycodone HCl” NCT06665048 ↗ “Drug: Oxycodone HCl” NCT07218549 ↗ “Oxycodone HCl 16 mg” NCT01280331 ↗ “Oxycodone HCl 8 mg” NCT01016808 ↗ |
| Known as | oxycodone HCl CR | “Patients were randomized (1:1) to receive oral tapentadol ER (25-200 mg bid) or oral oxycodone HCl CR (5-40 mg bid) for 4 weeks of double-blind treatment.” PMID 23937387 ↗ Aug 2013 |
| Known as | Oxycodone HCL IR | “Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days” NCT00364533 ↗ |
| Known as | oxycodone hydrochloride | “The purpose of this study is to characterize the long-term safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid experienced pediatric patients aged...” NCT01369615 ↗25“The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl) controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16...” NCT01192295 ↗ “An immediate-release oxycodone hydrochloride formulation (IRO-A) indicated for moderate to severe pain was designed (by adding functional excipients) to discourage tampering...” PMID 22717418 ↗ Jun 2012 “Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two...” PMID 31456431 ↗ Sep 2019 “Oxycodone hydrochloride and naloxone hydrochloride dihydrate combined oral prolonged release tablets (OXN PR), is the investigational product to be used in this study.” NCT01439100 ↗ “Oxycodone hydrochloride, a newer opioid with established analgesic effects in adult surgery, has been less studied in pediatric contexts.” NCT06665048 ↗ “Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours” NCT01160614 ↗ “naloxone (naloxone hydrochloride) + oxycodone (oxycodone hydrochloride)” NCT06390046 ↗ “Oxycodone hydrochloride 5 mg and Oxycodone extended-release 10 mg” NCT04448457 ↗ “oxycodone hydrochloride (HCl) controlled release (CR; 20-50 mg)” PMID 24985410 ↗ Jul 2014 “Oxycodone Hydrochloride 50mg/mL Administered as an Infusion” NCT00626600 ↗ “Oxycodone Hydrochloride is a strong opioid receptor agonist” NCT05510986 ↗ “Oxycodone hydrochloride tablet 30 mg” NCT00853736 ↗ “Oxycodone hydrochloride (OxyContin)” NCT00254631 ↗ “Drug: oxycodone hydrochloride” NCT00726830 ↗ “Drug: Oxycodone Hydrochloride” NCT05515822 ↗ “Drug: Oxycodone Hydrochloride” NCT03685188 ↗ |
| Known as | Oxycodone hydrochloride (HCl) | “ALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride (HCl), an opioid agonist, surrounding sequestered naltrexone HCl, an...” PMID 25724154 ↗ Apr 20153“patients were randomized (1:1:1) to twice-daily (bid) doses of placebo, tapentadol ER (100-250 mg), or oxycodone hydrochloride (HCl) controlled release (CR; 20-50 mg).” PMID 24985410 ↗ Jul 2014 “Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.” NCT01825447 ↗ “Oxycodone Hydrochloride (HCl) and Placebo in Recreational Opioid Users” NCT03996694 ↗ |
| Known as | Oxycodone hydrochloride (HCl) immediate-release (IR) tablets, 40 mg | “Oxycodone hydrochloride (HCl) immediate-release (IR) tablets, 40 mg” NCT05571345 ↗ |
| Known as | Oxycodone hydrochloride cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of codoxy | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of combunox | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of oxycet | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of percocet | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of percodan | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of percodan-demi | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of roxicet | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of roxilox | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of roxiprin | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of targiniq | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of troxyca | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of tylox | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone hydrochloride component of xartemis | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone Hydrochloride Injection | “Oxycodone（Oxycodone Hydrochloride Injection，IV）” NCT07326683 ↗ |
| Known as | Oxycodone Immediate-Release | “Drug: Oxycodone Immediate-Release” NCT00313014 ↗ |
| Known as | Oxycodone IR | “Drug: Oxycodone IR” NCT06423703 ↗ |
| Known as | Oxycodone terephthalate component of codoxy | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone terephthalate component of percodan | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone terephthalate component of percodan-demi | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone terephthalate component of roxiprin | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxycodone XL | “Oxycodone XL 20mg/day(20mg once a day, after high fat meal)” NCT01568450 ↗ |
| Known as | Oxycodone, Hameln (ATC code: N02A A05) | “Oxycodone, Hameln (ATC code: N02A A05)” NCT05639712 ↗ |
| Known as | Oxycodone, oxycontin | “Oxycodone, oxycontin” NCT01859715 ↗ |
| Known as | Oxycodone-Acetaminophen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04872283 ↗ |
| Known as | Oxycontin | “This was a multicenter, open-label, randomized (patients are assigned different treatments based on chance), dose-titration, parallel-group study characterizing the...” NCT00399048 ↗14“The objective of this open-label, randomized, two-period, crossover study was to evaluate the oral bioavailability of the Mallinckrodt controlled-release test tablet...” NCT00853268 ↗ “Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day,...” NCT06381063 ↗ “Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate...” NCT03176121 ↗ “OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery.” NCT03314792 ↗ “comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies” NCT03024515 ↗ “commercially available controlled-release tablet of oxycodone (OxyContin® 40 mg, Purdue Pharma L.P.)” NCT00853892 ↗ “Oral Oxycodone 20mg (Oxycontin) controlled release formulation” NCT01127906 ↗ “Crushed OxyContin (oxycodone) extended-release 40 mg tablet” NCT03475862 ↗ “Every 12 hours for control-released oxycodone (OxyContin®)” NCT03176199 ↗ “Oxycodone (OxyContin®, OxyIR®, Roxicodone®)” NCT06240390 ↗ “Oxycodone hydrochloride (OxyContin)” NCT00254631 ↗ |
| Known as | Oxycontin CR | “Oxycontin CR 10mg (Oxycodone 10mg, fasted)” NCT01568450 ↗ |
| Known as | OxyIR | “Oxycodone (OxyContin®, OxyIR®, Roxicodone®)” NCT06240390 ↗ |
| Known as | Oxylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Oxymorphone 3-methyl ether | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | OxyNEO | “a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®” NCT02101840 ↗ |
| Known as | OxyNorm | “An anticipated analgesia protocol composed of PARACETAMOL 1g +/- OXYNORM 5 mg or 10 mg according to patients weight and pain intensity as evaluated by a simple numeric rating...” NCT05821517 ↗11“Patients will take either control-released oxycodone (OxyContin® 10mg and 20mg) or immediate-released oxycodone (OxyNorm® 5mg) or both for initial dose and used it to titrate...” NCT03176121 ↗ “Patients will receive conservative treatment Acetaminophen (paracetamol) 1000 mg tid and pregabalin (lyrica) 75 mg bid; can be increased to 150 mg bid, oxycodone (oxynorm) 10mg IR PRN.” NCT07095569 ↗ “The efficacy of dose titration of OxyNorm™(Oxycodone) immediate-release capsules versus morphine immediate-release tablets in the treatment of cancer pain.” NCT01675622 ↗ “comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies” NCT03024515 ↗ “If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po.” NCT02678897 ↗ “OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine.” NCT03314792 ↗ “Oxycodone immediate release (Oxynorm) 10mg as required every 4 to 6 hours.” NCT06864312 ↗ “additional OxyNorm (Oxycodone), if requested by the patients” NCT01816581 ↗ “Every 6 hours for immediate-released oxycodone (OxyNorm®)” NCT03176199 ↗ “Oxynorm” NCT02094807 ↗ |
| Known as | Pavinal | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Percocet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02826551 ↗ |
| Known as | PF-00345439 | “To estimate the effect of food on the pharmacokinetics and relative bioavailability of oxycodone following oral administration of single 40 mg doses of PF 00345439 Formulation...” NCT02117583 ↗ |
| Known as | Proladone | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | PTI-821 | “PTI-821 (oxycodone) 40 mg extended release capsule” NCT03475862 ↗ |
| Known as | Reltebon | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Remoxy | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Roxicodone | “Roxicodone™ tablet 30 mg, single dose with food” NCT00853736 ↗1“Oxycodone (OxyContin®, OxyIR®, Roxicodone®)” NCT06240390 ↗ |
| Known as | Roxybond | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Shortec | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Xtampza | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Known as | Xtampza ER | “Xtampza ER (oxycodone)” NCT03588806 ↗ |
| Known as | Zomestine | ChEMBL registry synonym — accepted as the source's own label CHEMBL656 ↗ |
| Action | Activate | “Mu opioid receptor agonist” CHEMBL656 ↗1“opioid agonist” NCT01366014 ↗ |
| Modality | Other / unclassified | “Oxycodone is a semisynthetic strong opioid analgesic” NCT03024515 ↗ |
| Route | Oral | “15 mg/70 kg oxycodone administered once per day, orally.” NCT00158184 ↗ |
| Target | OPRM1 | “Mu opioid receptor agonist” CHEMBL656 ↗ |